Natalie Burrows,Rachael Bashford-Rogers,Vijesh J. Bhute,Ana Peñalver,John R. Ferdinand,Benjamin Stewart,Joscelin E. G. Smith,Mukta Deobagkar‐Lele,Girolamo Giudice,Thomas M. Connor,Akimichi Inaba,Laura Bergamaschi,Sam Smith,Maxine Tran,Evangelia Petsalaki,Paul Lyons,Marion Espéli,Brian J.P. Huntly,Kenneth G. C. Smith,Richard J. Cornall
B lymphocyte development and selection are central to adaptive immunity and self-tolerance. These processes require B cell receptor (BCR) signaling and occur in bone marrow, an environment with variable hypoxia, but whether hypoxia-inducible factor (HIF) is involved is unknown. We show that HIF activity is high in human and murine bone marrow pro-B and pre-B cells and decreases at the immature B cell stage. This stage-specific HIF suppression is required for normal B cell development because genetic activation of HIF-1α in murine B cells led to reduced repertoire diversity, decreased BCR editing and developmental arrest of immature B cells, resulting in reduced peripheral B cell numbers. HIF-1α activation lowered surface BCR, CD19 and B cell–activating factor receptor and increased expression of proapoptotic BIM. BIM deletion rescued the developmental block. Administration of a HIF activator in clinical use markedly reduced bone marrow and transitional B cells, which has therapeutic implications. Together, our work demonstrates that dynamic regulation of HIF-1α is essential for normal B cell development. B cell development and selection occur in the often hypoxic environment of the bone marrow. Burrows and colleagues demonstrate that dynamic regulation of B cell–intrinsic hypoxia-inducible factor-1α is essential for normal B cell development and function.